Scarica l'app Stockscreener
53.75
1.52%
-0.83
Dopo l'orario di chiusura:
54.31
0.56
+1.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GPCR Giù?
Forum
Previsione
Precedente Chiudi:
$54.58
Aprire:
$55
Volume 24 ore:
587.36K
Relative Volume:
0.42
Capitalizzazione di mercato:
$3.81B
Reddito:
-
Utile/perdita netta:
$-141.43M
Rapporto P/E:
-21.87
EPS:
-2.4581
Flusso di cassa netto:
$-226.41M
1 W Prestazione:
-6.89%
1M Prestazione:
-23.29%
6M Prestazione:
+157.05%
1 anno Prestazione:
+163.48%
Intervallo 1D:
$52.51
$56.00
Intervallo di 1 settimana:
$52.51
$60.61
Portata 52W:
$13.22
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Nome
Structure Therapeutics Inc Adr
Settore
Industria
Telefono
(650) 457-1978
Indirizzo
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
53.75 | 3.81B | 0 | -141.43M | -226.41M | -2.4581 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-02 | Iniziato | Citigroup | Buy |
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2025-01-08 | Iniziato | Stifel | Buy |
| 2024-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-21 | Iniziato | JP Morgan | Overweight |
| 2024-04-09 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-07-27 | Iniziato | Piper Sandler | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2023-02-28 | Iniziato | BMO Capital Markets | Outperform |
| 2023-02-28 | Iniziato | Guggenheim | Buy |
| 2023-02-28 | Iniziato | Jefferies | Buy |
| 2023-02-28 | Iniziato | SVB Securities | Outperform |
Mostra tutto
Structure Therapeutics Inc Adr Borsa (GPCR) Ultime notizie
Assessing Structure Therapeutics (GPCR) Valuation After Its Quarterly Profit Turnaround - Sahm
Why Structure Therapeutics (GPCR) Is Down 7.6% After Swinging to Q4 Profit and Filing a $236M Shelf RegistrationAnd What's Next - Sahm
Jefferies Financial Group Inc. Acquires New Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Structure Therapeutics inks major GLP-1 licensing deal - MSN
Rhenman & Partners Asset Management AB Purchases 45,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Trading Systems Reacting to (GPCR) Volatility - Stock Traders Daily
Research Analysts Offer Predictions for GPCR Q1 Earnings - Defense World
Tax withholding trims Structure Therapeutics (NASDAQ: GPCR) CMO stake - Stock Titan
Structure Therapeutics (GPCR) CDO reports tax share and ESPP transactions - Stock Titan
HC Wainwright Issues Negative Estimate for GPCR Earnings - MarketBeat
Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? - TradingView
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million - AOL.com
GPCR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Handelsbanken Fonder AB Sells 212,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position - AOL.com
Structure Therapeutics (NASDAQ:GPCR) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Structure Therapeutics price target on competitive positioning - Investing.com
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Sold by Monashee Investment Management LLC - MarketBeat
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR) and BrightSpring Health Services, Inc. (BTSG) - The Globe and Mail
Did New Shelf Registration and Oral GLP-1 Progress Just Shift Structure Therapeutics' (GPCR) Investment Narrative? - Sahm
Guggenheim Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Structure Therapeutics (NASDAQ:GPCR) Upgraded by Wall Street Zen to Hold Rating - Defense World
Structure Therapeutics shares could rise on obesity drug data, Cantor says - Investing.com India
Structure Therapeutics (NASDAQ:GPCR) Price Target Cut to $113.00 by Analysts at Citizens Jmp - MarketBeat
Citizens cuts Structure Therapeutics stock price target on pipeline expansion - Investing.com
Structure Therapeutics (NASDAQ:GPCR) Releases Earnings Results, Misses Expectations By $0.14 EPS - MarketBeat
Structure Therapeutics Inc. SEC 10-K Report - TradingView
Structure Therapeutics (NASDAQ: GPCR) turns Q4 profit as obesity pipeline advances - Stock Titan
Obesity pill aleniglipron trims 15% weight as maker turns quarterly profit - Stock Titan
Private Capital Advisors Inc. Buys New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Alpha Tau Medical Ltd (DRTS) and Oric Pharmaceuticals (ORIC) - The Globe and Mail
How Structure Therapeutics Inc. (GPCR) Affects Rotational Strategy Timing - Stock Traders Daily
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX) - The Globe and Mail
Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026 - TradingView
Structure Therapeutics Inc. (GPCR): Analyst Consensus Points To A 60% Upside Potential - DirectorsTalk Interviews
GPCRStructure Therapeutics Inc ADR Latest Stock News & Market Updates - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Guardant Health (GH) and PTC Therapeutics (PTCT) - The Globe and Mail
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake - AOL.com
Structure Therapeutics (GPCR) Gained from Favorable Clinical Data - Finviz
Aberdeen Group plc Boosts Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Structure Therapeutics (GPCR) Projected to Post Earnings on Thursday - MarketBeat
Structure Therapeutics surges on phase 2 data for GLP-1 pill aleniglipron - MSN
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and West Pharmaceutical Services (WST) - The Globe and Mail
Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition? - TradingView
Readystate Asset Management LP Increases Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Palvella Therapeutics (PVLA) - The Globe and Mail
BVF group discloses 4.9% Structure Therapeutics (GPCR) holding - Stock Titan
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Short Interest Down 17.8% in January - MarketBeat
(GPCR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
FY2030 Earnings Forecast for GPCR Issued By HC Wainwright - MarketBeat
Structure Therapeutics Inc Adr Azioni (GPCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):